Systemic effects of the hormonal treatment of male hypogonadism with preliminary indications for the management of COVID-19 patients.
benign prostate hyperplasia
hypogonadism
obesity
obstructive sleep apnea
prostate cancer
prostatitis
testosterone replacement therapy
type 2 diabetes mellitus
Journal
Therapeutic advances in endocrinology and metabolism
ISSN: 2042-0188
Titre abrégé: Ther Adv Endocrinol Metab
Pays: United States
ID NLM: 101532143
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
05
2020
accepted:
24
09
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
3
11
2020
Statut:
epublish
Résumé
Male hypogonadism, defined as an inadequate production of testosterone (T), is associated with a greater morbidity and mortality. Epidemiological studies identified T deficiency as a risk factor for cardiovascular disease. Also, low serum T levels impact on glucose homeostasis through a worse glucose uptake, utilization, and disposal, and the general negative impact on metabolism. The aim of this review is to provide a comprehensive and updated overview of the effects of T replacement therapy on metabolic and cardiovascular systems and prostate tissue in patients with hypogonadism, including molecular mechanisms through which T exerts its actions. Furthermore, recent findings on novel coronavirus disease (COVID-19) epidemiology have shown a greater mortality in male compared with female patients and a role of T in promoting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection of the host cells has been demonstrated. Hence, the secondary aim of this review is to provide preliminary indications on the management in patients with COVID-19.
Identifiants
pubmed: 33133492
doi: 10.1177/2042018820966438
pii: 10.1177_2042018820966438
pmc: PMC7576928
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2042018820966438Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
J Clin Endocrinol Metab. 2018 Feb 1;103(2):681-688
pubmed: 29253154
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3097-3107
pubmed: 30835274
Am J Clin Exp Urol. 2018 Apr 01;6(2):62-77
pubmed: 29666834
Sci Rep. 2017 Aug 10;7(1):7801
pubmed: 28798373
BJU Int. 2015 Nov;116(5):791-6
pubmed: 25601421
Diabetes Care. 2016 Jan;39(1):82-91
pubmed: 26622051
Urology. 2016 Feb;88:22-32
pubmed: 26616095
PLoS One. 2015 May 26;10(5):e0127515
pubmed: 26010093
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Eur J Endocrinol. 2017 Aug;177(2):157-168
pubmed: 28522646
J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235486
Int J Obes Relat Metab Disord. 1992 Dec;16(12):991-7
pubmed: 1335979
Clin Endocrinol (Oxf). 2020 Nov;93(5):555-563
pubmed: 32633813
Curr Treat Options Oncol. 2006 Sep;7(5):363-9
pubmed: 16904053
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Eur J Endocrinol. 2009 May;160(5):839-46
pubmed: 19174534
Am Heart J. 2002 Aug;144(2):359-64
pubmed: 12177657
J Endocrinol. 2013 Apr 29;217(3):R25-45
pubmed: 23378050
J Endocrinol. 2014 Jan 27;220(3):R37-55
pubmed: 24353306
Fertil Steril. 2020 Jun;113(6):1135-1139
pubmed: 32482249
JAMA Intern Med. 2017 Apr 1;177(4):491-499
pubmed: 28241244
Aging Male. 2018 Sep;21(3):158-169
pubmed: 29708829
Ann Oncol. 2020 Aug;31(8):1040-1045
pubmed: 32387456
Clin Endocrinol (Oxf). 2014 Nov;81(5):746-53
pubmed: 24645738
J Immunol. 1997 Feb 1;158(3):1310-4
pubmed: 9013974
Cancer Discov. 2014 Nov;4(11):1310-25
pubmed: 25122198
Endocr Rev. 2018 Jun 1;39(3):369-386
pubmed: 29522088
Urologiia. 2018 Mar;(1):71-76
pubmed: 29634137
Eur Urol Focus. 2019 Jul;5(4):539-544
pubmed: 30858073
Biomed Res Int. 2014;2014:392432
pubmed: 25110677
Diabetes Care. 2014 Aug;37(8):2098-107
pubmed: 24804695
Am J Physiol Renal Physiol. 2005 Nov;289(5):F941-8
pubmed: 16210452
Mol Cell Endocrinol. 2018 Jan 15;460:14-23
pubmed: 28606867
Aging Male. 2018 Dec;21(4):272-280
pubmed: 29378485
Endocrinology. 2010 Feb;151(2):628-38
pubmed: 20022929
J Clin Oncol. 2017 May 1;35(13):1430-1436
pubmed: 28447913
Am J Physiol Regul Integr Comp Physiol. 2017 Apr 1;312(4):R501-R510
pubmed: 28100475
Eur J Endocrinol. 2011 Nov;165(5):687-701
pubmed: 21852391
Eur J Endocrinol. 2009 Sep;161(3):443-9
pubmed: 19542238
Ann Pharmacother. 2014 Jul 2;48(9):1138-1144
pubmed: 24989174
Eur Heart J. 2015 Oct 21;36(40):2706-15
pubmed: 26248567
Arch Endocrinol Metab. 2017 May-Jun;61(3):282-287
pubmed: 28225990
Res Pract Thromb Haemost. 2020 Mar 11;4(3):422-428
pubmed: 32211576
Eur J Endocrinol. 2006 Jun;154(6):899-906
pubmed: 16728551
J Clin Invest. 1993 Jul;92(1):91-8
pubmed: 8326021
Basic Clin Androl. 2019 Mar 29;29:5
pubmed: 30976419
Am J Cardiol. 2016 Mar 1;117(5):794-9
pubmed: 26772440
J Am Coll Cardiol. 2011 Oct 11;58(16):1674-81
pubmed: 21982312
Am J Med. 2019 Sep;132(9):1069-1077.e4
pubmed: 30953635
J Cardiovasc Pharmacol Ther. 2018 Nov;23(6):543-550
pubmed: 29929385
J Cell Biochem. 2015 Jun;116(6):998-1006
pubmed: 25639671
Circulation. 2019 Jun 18;139(25):e1144-e1161
pubmed: 30586775
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
BJU Int. 2009 Jan;103(1):62-4
pubmed: 18671790
Drug Saf. 2016 Feb;39(2):117-30
pubmed: 26482385
Circulation. 2000 Oct 17;102(16):1906-11
pubmed: 11034937
N Engl J Med. 2010 Jul 8;363(2):109-22
pubmed: 20592293
Pancreas. 2010 Mar;39(2):193-200
pubmed: 20093993
J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744
pubmed: 29562364
Curr Urol Rep. 2016 Jun;17(6):46
pubmed: 27068735
J Endocrinol Invest. 2018 Jan;41(1):49-57
pubmed: 28711970
Clin Endocrinol (Oxf). 2003 Jul;59(1):62-7
pubmed: 12807505
Int J Cardiol. 2010 Jun 25;142(1):50-5
pubmed: 19361872
J Urol. 2004 Sep;172(3):920-2
pubmed: 15310998
Am J Med. 2017 Mar;130(3):293-305
pubmed: 27751897
J Clin Endocrinol Metab. 2014 Jan;99(1):E9-18
pubmed: 24257908
Am J Cardiol. 2019 Oct 15;124(8):1171-1178
pubmed: 31409450
J Clin Endocrinol Metab. 2011 Oct;96(10):3007-19
pubmed: 21816776
Hosp Pract (1995). 2018 Apr;46(2):47-55
pubmed: 29478348
Andrology. 2014 Nov;2(6):819-34
pubmed: 25269643
Maturitas. 2017 Dec;106:31-37
pubmed: 29150164
J Sex Med. 2017 Nov;14(11):1307-1317
pubmed: 29110802
Asian J Androl. 2018 Mar-Apr;20(2):120-130
pubmed: 29442075
Coron Artery Dis. 2016 Mar;27(2):95-103
pubmed: 26554661
Eur Urol. 2017 Aug;72(2):164-167
pubmed: 28249799
J Steroid Biochem Mol Biol. 2017 Mar;167:106-114
pubmed: 27888135
Asian J Androl. 2014 Mar-Apr;16(2):223-31
pubmed: 24407187
Vasc Health Risk Manag. 2018 Oct 15;14:283-290
pubmed: 30410343
Andrology. 2020 Sep;8(5):970-987
pubmed: 32026626
Aging Male. 2019 Dec;22(4):241-249
pubmed: 30235049
Sex Med Rev. 2016 Oct;4(4):376-88
pubmed: 27474995
J Endocrinol Invest. 2017 Jul;40(7):705-712
pubmed: 28258556
Ann Intern Med. 2018 Mar 6;168(5):351-358
pubmed: 29357392
JAMA Netw Open. 2020 May 1;3(5):e208292
pubmed: 32379329
J Cardiovasc Pharmacol Ther. 2017 Sep;22(5):414-433
pubmed: 28421834
Trends Endocrinol Metab. 2019 Dec;30(12):879-890
pubmed: 31471249
Circ Heart Fail. 2012 May 1;5(3):315-21
pubmed: 22511747
Heart. 2004 Aug;90(8):871-6
pubmed: 15253956
Int J Mol Sci. 2020 Apr 22;21(8):
pubmed: 32331343
Am Heart J. 2012 Dec;164(6):893-901
pubmed: 23194490
BJU Int. 2018 May;121(5):811-818
pubmed: 29383868
Front Endocrinol (Lausanne). 2020 Mar 13;11:110
pubmed: 32231640
J Am Heart Assoc. 2017 Oct 17;6(10):
pubmed: 29042425
J Clin Endocrinol Metab. 1995 Jan;80(1):239-43
pubmed: 7829619
Metabolism. 2018 Sep;86:61-68
pubmed: 29656047
Pharmacotherapy. 2015 Jan;35(1):72-8
pubmed: 25582846
Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S59-63
pubmed: 10997611
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
J Urol. 2005 Feb;173(2):533-6
pubmed: 15643240
J Korean Med Sci. 2020 Mar 16;35(10):e112
pubmed: 32174069
Hypertens Res. 2005 Aug;28(8):625-30
pubmed: 16392765
J Clin Endocrinol Metab. 2016 Jan;101(1):69-78
pubmed: 26509870
Eur J Pharmacol. 2012 Jun 5;684(1-3):116-24
pubmed: 22484505
Am J Cardiol. 2008 Mar 1;101(5):618-24
pubmed: 18308009